ArticlePLoS medicine2026

SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation.

Shih-Chieh Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.